WO2000067738A3 - Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires - Google Patents
Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires Download PDFInfo
- Publication number
- WO2000067738A3 WO2000067738A3 PCT/US2000/012339 US0012339W WO0067738A3 WO 2000067738 A3 WO2000067738 A3 WO 2000067738A3 US 0012339 W US0012339 W US 0012339W WO 0067738 A3 WO0067738 A3 WO 0067738A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tyrosine kinase
- protein tyrosine
- prophylactic
- kinase pathway
- therapeutic treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000616765A JP4920134B2 (ja) | 1999-05-07 | 2000-05-05 | 眼障害の処置におけるプロテインチロシンキナーゼ経路インヒビターの使用 |
MXPA01011344A MXPA01011344A (es) | 1999-05-07 | 2000-05-05 | El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares. |
EP00932108A EP1178791A2 (fr) | 1999-05-07 | 2000-05-05 | Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires |
CA2373178A CA2373178C (fr) | 1999-05-07 | 2000-05-05 | Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires |
AU49884/00A AU774495B2 (en) | 1999-05-07 | 2000-05-05 | The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13311299P | 1999-05-07 | 1999-05-07 | |
US60/133,112 | 1999-05-07 | ||
US35044099A | 1999-07-09 | 1999-07-09 | |
US09/350,440 | 1999-07-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000067738A2 WO2000067738A2 (fr) | 2000-11-16 |
WO2000067738A3 true WO2000067738A3 (fr) | 2001-08-23 |
Family
ID=26831056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012339 WO2000067738A2 (fr) | 1999-05-07 | 2000-05-05 | Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1178791A2 (fr) |
JP (1) | JP4920134B2 (fr) |
AU (1) | AU774495B2 (fr) |
CA (1) | CA2373178C (fr) |
MX (1) | MXPA01011344A (fr) |
WO (1) | WO2000067738A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2826276A1 (fr) * | 2001-06-20 | 2002-12-27 | Raouf Rekik | Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie |
US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
WO2007076358A1 (fr) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | Preparation pharmaceutique pour l'administration, dans l'oeil, de composes inhibiteurs des récepteurs tyrosine kinases (rtki) |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
WO2019146738A1 (fr) * | 2018-01-25 | 2019-08-01 | 国立大学法人大阪大学 | Procédé de détection d'état de stress et dispositif de détection de stress |
CN114931574A (zh) * | 2022-06-14 | 2022-08-23 | 深圳爱尔眼科医院 | 一种铁死亡抑制剂及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040090A1 (fr) * | 1997-03-14 | 1998-09-17 | The Regents Of The University Of California | Methodes d'inhibition de cytotoxicite bacterienne |
WO1999045920A2 (fr) * | 1998-03-13 | 1999-09-16 | Johns Hopkins University School Of Medicine | Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09316000A (ja) * | 1996-05-31 | 1997-12-09 | Toagosei Co Ltd | 血管新生抑制用ワクチン |
ES2253787T3 (es) * | 1996-11-05 | 2006-06-01 | The Children's Medical Center Corporation | Composiciones para inhibicion de la angiogenesis que comprenden talidomida y un nsaid. |
EP1017682A4 (fr) * | 1997-09-26 | 2000-11-08 | Merck & Co Inc | Nouveaux inhibiteurs de l'angiogenese |
-
2000
- 2000-05-05 JP JP2000616765A patent/JP4920134B2/ja not_active Expired - Fee Related
- 2000-05-05 MX MXPA01011344A patent/MXPA01011344A/es active IP Right Grant
- 2000-05-05 EP EP00932108A patent/EP1178791A2/fr not_active Withdrawn
- 2000-05-05 CA CA2373178A patent/CA2373178C/fr not_active Expired - Fee Related
- 2000-05-05 AU AU49884/00A patent/AU774495B2/en not_active Ceased
- 2000-05-05 WO PCT/US2000/012339 patent/WO2000067738A2/fr active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998040090A1 (fr) * | 1997-03-14 | 1998-09-17 | The Regents Of The University Of California | Methodes d'inhibition de cytotoxicite bacterienne |
WO1999045920A2 (fr) * | 1998-03-13 | 1999-09-16 | Johns Hopkins University School Of Medicine | Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine |
Non-Patent Citations (5)
Title |
---|
CASAGRANDE F. ET AL: "G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27(Kip1) and inhibition of G1 CDKs in choroidal melanoma cells.", FEBS LETTERS, (6 FEB 1998) 422/3 (385-390)., XP000971946 * |
FAURE VIOLAINE ET AL: "Tyrosine kinase inhibitors and antioxidants modulate NF-kappaB and NOS-II induction in retinal epithelial cells.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 275, no. 1 PART1, July 1998 (1998-07-01), pages C208 - C215, XP000978431, ISSN: 0002-9513 * |
HAYASHI A ET AL: "Genistein, a protein tyrosine kinase inhibitor, ameliorates retinal degeneration after ischemia-reperfusion injury in rat.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 38, no. 4 PART 1-2, 1997, Annual Meeting of the Association for Research in Vision and Ophthalmology, Parts 1-2;Fort Lauderdale, Florida, USA; May 11-16, 1997, pages S101, XP000978471, ISSN: 0146-0404 * |
See also references of EP1178791A2 * |
YOON H.S. ET AL: "Genistein produces reduction in growth and induces apoptosis of rat RPE-J cells.", CURRENT EYE RESEARCH, (2000) 20/3 (215-224)., XP000978532 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002544159A (ja) | 2002-12-24 |
CA2373178A1 (fr) | 2000-11-16 |
AU774495B2 (en) | 2004-07-01 |
AU4988400A (en) | 2000-11-21 |
JP4920134B2 (ja) | 2012-04-18 |
EP1178791A2 (fr) | 2002-02-13 |
WO2000067738A2 (fr) | 2000-11-16 |
MXPA01011344A (es) | 2004-06-03 |
CA2373178C (fr) | 2013-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2321560A1 (fr) | Traitement de la retinopathie diabetique ou des inflammations oculaires au moyen d'un inhibiteur des tyrosine-kinases tel que la genisteine | |
WO2001009118A3 (fr) | Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire | |
Gros | Spasticity—clinical classification and surgical treatment | |
WO1998010767A3 (fr) | Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs | |
NO970517L (no) | Topiske oftalmiske formuleringer inneholdende doxepinderivater for behandling av öyenallergisykdommer | |
CA2502437A1 (fr) | Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome | |
EP2514420A3 (fr) | Utilisation de rapamycine pour le traitement ou la prévention de la dégénération maculaire liée à l'âge | |
WO2006071548A3 (fr) | Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase | |
HK1069851A1 (en) | Bone morphogenic proteins (bmp), bmp receptors andbmp binding proteins and their use in the diagnosis and treatment of glaucoma | |
TW200833341A (en) | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | |
WO2003000343A3 (fr) | Administration d'inhibiteurs de phosphodiesterase destinee au traitement de l'ejaculation precoce | |
MX9702349A (es) | Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma. | |
CA2265839A1 (fr) | Manchons dotes de noeuds pour dispositifs prothetiques transcutanes ou intracorporels | |
CA2582316A1 (fr) | Utilisation d'inhibiteurs de jun n-terminal kinases pour le traitement de la retinopathie glaucomateuse et de maladies oculaires | |
WO2005102303A3 (fr) | Antiprostaglandines pour le traitement de pathologies oculaires | |
CA2314571A1 (fr) | Methodes et compositions pour traiter des maladies et des affections de l'oeil | |
CA2262268C (fr) | Methode pour traiter l'impuissance causee par des lesions a la moelle epiniere | |
WO2000067738A3 (fr) | Utilisation d'un inhibiteur de trajet de proteine tyrosine kinase dans le traitement des troubles oculaires | |
WO2002047673A3 (fr) | Methodes et compositions pour le traitement d'etats pathologiques associes a la neovascularisation | |
WO2002051379A3 (fr) | Aerosol nasal thixotropique | |
WO2002013805A3 (fr) | Procede pour traiter des troubles neurodegeneratifs de la retine et de la papille optique | |
EP1037622A4 (fr) | Derives de la taurine pour le traitement de troubles ophtalmiques | |
IT1276462B1 (it) | Diamidi aromatiche acide ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico | |
WO1998024898A3 (fr) | Composition therapeutique contenant la proteine kal et utilisation de la proteine kal pour le traitement de lesions retiniennes, renales, neuronales et neurales | |
WO2004087157A3 (fr) | Thérapie combinée destinée à la maladie d'alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 49884/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2373178 Country of ref document: CA Ref country code: CA Ref document number: 2373178 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 2000 616765 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/011344 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000932108 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000932108 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 49884/00 Country of ref document: AU |